NCT03877406

Effect of Empagliflozin on Body Composition and Ketones

Decrease in Body Fat and Increase in Ketone Body After 6-month Treatment of Empagliflozin in Korean Patients With Type 2 Diabetes

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Seoul National University Bundang Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).

Detailed description

Sodium-glucose cotransporter-2 (SGLT2) inhibitor increases urinary excretion of glucose, promoting glycemic control and weight loss. However, it is unclear whether weight loss is attributed to decrease in fat components and associated with favorable changes in metabolic profile. The purpose of this study is to evaluate changes of body composition induced by SGLT2 inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).

Conditions

• Diabetes Mellitus
• Fat; Intolerance, Pancreas

Interventions

Type	Name	Description
DRUG	Empagliflozin 10 MG	addition of empagliflozin 10 MG
DRUG	Hypoglycemics Oral	dose escalation of hypoglycemics oral

Timeline

• Start date: 2018-08-01
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2019-03-15
• Last updated: 2023-08-14

Locations

1 site across 1 country: South Korea

Regulatory

• FDA-regulated drug study